Skip to main content

Peer Review reports

From: Use of maximal dosage renin-angiotensin-aldosterone system inhibitors in a real life population of complicated type 2 diabetes – contraindications and opportunities

Original Submission
15 Dec 2021 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
12 Oct 2022 Reviewed Reviewer Report
8 Feb 2023 Reviewed Reviewer Report
17 Mar 2023 Author responded Author comments - C.M. Gant
Resubmission - Version 3
17 Mar 2023 Submitted Manuscript version 3
8 May 2023 Reviewed Reviewer Report
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
18 May 2023 Editorially accepted
16 Aug 2023 Article published 10.1186/s12882-023-03205-2

You can find further information about peer review here.

Back to article page